Veklury May Reduce Risk for Long COVID
Remdesivir (Veklury, Gilead) appears to reduce the risk for certain long-COVID symptoms in people who were hospitalized for COVID-19.
Gilead researchers analyzed HealthVerity data from 52,006 patients and found using remdesivir, a nucleotide analog prodrug, was associated with a 10% lower risk for any long-COVID symptom in patients.
In patients 65 and older, remdesivir lowered the risk for six of 16 individual symptoms (including cognitive dysfunction,